In vitro combinations of natamycin with voriconazole, itraconazole and micafungin against clinical Fusarium strains causing keratitis

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 4, 2016, Pages 953-955

  Al Hatmi, Abdullah M S ^a,b,c   Meletiadis, Joseph ^d   Curfs Breuker, Ilse ^e   Bonifaz, Alexandro ^f   Meis, Jacques F ^e,g   De Hoog, G Sybren ^a,b,h,i  

^a CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c MINISTRY OF HEALTH   (Oman)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^f SECRETARÍA DE SALUD   (Mexico)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

ⁱ KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; MICAFUNGIN; NATAMYCIN; VORICONAZOLE; ANTIFUNGAL AGENT; DRUG COMBINATION; ECHINOCANDIN; LIPOPEPTIDE;

ARTICLE; BROTH DILUTION; DRUG POTENTIATION; FRACTIONAL INHIBITORY CONCENTRATION INDEX; FUNGAL STRAIN; FUSARIUM; FUSARIUM FALCIFORME; FUSARIUM NAPIFORME; FUSARIUM PETROLIPHILUM; FUSARIUM PROLIFERATUM; FUSARIUM PSEUDENSIFORME; FUSARIUM SACCHARI; IN VITRO STUDY; KERATOMYCOSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; DERMATOMYCOSES; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; FUSARIOSIS; KERATITIS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTIFUNGAL AGENTS; DERMATOMYCOSES; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG SYNERGISM; ECHINOCANDINS; FUSARIOSIS; FUSARIUM; ITRACONAZOLE; KERATITIS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; VORICONAZOLE;

EID: 84964334650     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv421     Document Type: Article

References (19)

1. Thomas PA, Leck AK, Myatt M. Characteristic clinical features as an aid to the diagnosis of suppurative keratitis caused by filamentous fungi. Br J Ophthalmol 2005; 89: 1554-8.
2. Oechsler RA, Yamanaka TM, Bispo PJM et al. Fusarium keratitis in Brazil: genotyping, in vitro susceptibilities, and clinical outcomes. Clin Ophthalmol 2013; 7: 1693-701.
3. Al-Hatmi AM, Bonifaz A, de Hoog GS et al. Keratitis by Fusarium temperatum, a novel opportunist. BMC Infect Dis 2014; 14: 588.
4. Kredics L, Narendran V, Shobana CS et al. Filamentous fungal infections of the cornea: a global overview of epidemiology and drug sensitivity. Mycoses 2015; 58: 243-60.
5. Lin H-C, Lin J-L, Lin-Tan D-T et al. Early keratectomy in the treatment of moderate Fusarium keratitis. PLoS One 2012; 7: e42126.
6. Al-Hatmi AM, van Diepeningen A, Curfs-Breuker I et al. Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex. J Antimicrob Chemother 2015; 70: 1068-71.
7. Johnson MD, MacDougall C, Ostrosky-Zeichner L et al. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48: 693-715.
8. Prajna NV, Krishnan T, Mascarenhas J et al. Themycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole. JAMA Ophthalmol 2013; 131: 422-9.
9. Sharma S, Das S, Virdi A et al. Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial. Br J Ophthalmol 2015; 99: 1-6.
10. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi-Second Edition: Approved Standard M38-A2. CLSI, Wayne, PA, USA, 2008.
11. Meletiadis J, Mouton JW, Rodriguez-Tudela J et al. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporum prolificans. Antimicrob Agents Chemother 2000; 44: 470-2.
12. Arikan S, Lozano-Chiu M, Paetznick V et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46: 245-7.
13. Te Dorsthorst DT, Zwaaftink RB, Rijs AJ et al. A colorimetric and spectrophotometric method for in vitro susceptibility testing of Aspergillus species against caspofungin. Med Mycol 2007; 45: 351-5.
14. Hariprasad SM, Mieler WF, Lin TK et al. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol 2008; 92: 871-8.
15. Sun CQ, Lalitha P, Prajna NV et al. Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis. Ophthalmology 2014; 121: 1495-500.
16. Azor M, Gené J, Cano J et al. Less frequent Fusarium species of clinical interest: correlation between morphological and molecular identification and antifungal susceptibility. J ClinMicrobiol 2009; 47: 1463-8.
17. Spader TB, Venturini TP, Rossatob L et al. Synergism of voriconazole or itraconazole with other antifungal agents against species of Fusarium. Rev Iberoam Micol 2013; 30: 200-4.
18. Li L, Wang Z, Li R et al. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients. Am J Ophthalmol 2008; 146: 724-8.
19. Kalavathy CM, Parmar P, Kaliamurthy J et al. Comparison of topical itraconazole 1% with topical natamycin 5% for the treatment of filamentous fungal keratitis. Cornea 2005; 24: 449-52.